Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLynn Macdonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
Estimating the term…
Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.
A mouse comprising a genetic modification, wherein the genetic modification comprises a replacement of endogenous low affinity FcγR genes with at least two low affinity human FcγR genes placed at the endogenous mouse low affinity FcγR gene locus, and wherein the mouse comprises a functional FcR γ-chain.
A genetically modified mouse, wherein the genetic modification comprises a replacement of endogenous mouse genes encoding FcγRIIB, FcγRIII, and FcγRIV α-subunits with a gene encoding a human FcγRIIIA α-subunit, wherein the mouse expresses a human FcγRIIIA protein associated with an endogenous mouse FcR γ-subunit, wherein the human FcγRIIIA protein is expressed on the surface of a mouse NK cell.
A method for measuring therapeutic-dependent cell killing, comprising:
Dependencies are inferred from the claim text.